Suspect Science Leads to Pause in Stem Cell Trial. Kaiser, J. 362(6414):513.
Suspect Science Leads to Pause in Stem Cell Trial [link]Paper  doi  abstract   bibtex   
[Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how – and whether – the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]
@article{kaiserSuspectScienceLeads2018,
  title = {Suspect Science Leads to Pause in Stem Cell Trial},
  author = {Kaiser, Jocelyn},
  date = {2018-11},
  journaltitle = {Science},
  volume = {362},
  pages = {513},
  issn = {0036-8075},
  doi = {10.1126/science.362.6414.513},
  url = {https://doi.org/10.1126/science.362.6414.513},
  abstract = {[Excerpt] [...] In mid-October, Harvard University officials disclosed that they have called for the retraction of 31 papers [...] studying the potential of stem cells to repair the heart. And this week, federal officials paused a related clinical study, explaining that the pending retractions ” have raised concerns about the scientific foundations of this trial.” [...] Some critics of his work say studies like the now-halted trial should never have started, given long-standing questions about how -- and whether -- the cells Anversa studied might repair heart tissue. ” The problem is that if you don't know how something works, then you don't really have a road map of what to address to make it better,” says Deepak Srivastava, a pediatric cardiologist and president of the Gladstone Institutes in San Francisco, California. [...] Further concerns arose this month when Harvard and Brigham and Women's recommended that 31 papers from the Anversa lab be retracted because they ” included falsified and/or fabricated data.” [...] some researchers think the trial should be completed. ” There's plenty of reason to believe that there's still promise,” says cardiologist Christopher Granger of Duke University in Durham, North Carolina. Bolli [...] points to ” overwhelming evidence” from animal studies that c-kit+ cells somehow promote heart tissue growth. ” The controversy [...] does not really change the validity of using c-kit+ cells,” Bolli says. [...]},
  keywords = {*imported-from-citeulike-INRMM,~INRMM-MiD:c-14652919,epistemology,publication-bias,publish-or-perish,research-management,science-ethics,scientific-community-self-correction,scientific-misconduct},
  number = {6414}
}
Downloads: 0